New treatment for inoperable pancreatic cancer form offers hope. Here's what Optune Pax does.

For the first time in 30 years, the Food and Drug Administration has approved a new treatment for an inoperable type of pancreatic cancer​.
JD Supra

Novacure’s Wearable Lung Cancer Treatment Device, Optune Lua, Receives FDA Approval

The FDA has granted approval for Novocure‘s wearable medical device, Optune Lua, designed to treat advanced non-small cell lung cancer (NSCLC). The device utilizes portable transducer arrays placed on ...

Novocure's Optune Lua Gets Japan Reimbursement for NSCLC Treatment

NVCR gains Japan NHI reimbursement for Optune Lua in advanced NSCLC, expanding patient access and supporting adoption of its ...
Hoodline

FDA Backs Wearable Electric-Field Device For Tough-To-Treat Pancreatic Cancer

FDA leaders framed the approval as a step forward for a cancer that has seen few therapeutic breakthroughs, stressing that the pancreatic cancer community deserves better options. The agency also ...
Business Insider

FDA Approves First-of-Its-Kind Device to Treat Pancreatic Cancer

White Oak, Md., Feb. 12, 2026 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration has approved a first-of-its-kind device for the treatment of adult patients with locally advanced pancreatic ...
Medical Xpress

FDA approves noninvasive Optune Pax device for advanced pancreatic cancer

The U.S. Food and Drug Administration has approved a first-of-its-kind, noninvasive device, the Optune Pax, for the treatment of adult patients with locally advanced pancreatic cancer. Approval of ...
Hosted on MSN

Novocure stock surges nearly 30% after hours: FDA clears first new pancreatic cancer therapy in almost three decades

・The FDA approved Optune Pax for locally advanced pancreatic cancer. ・The Panova-3 trial showed Optune Pax, used alongside standard chemotherapy, improved median overall survival and delayed pain ...
MarketWatch

U.S. FDA Approves Novocure's Optune Pax(R) for the Treatment of Locally Advanced Pancreatic Cancer

The MarketWatch News Department was not involved in the creation of this content. Optune Pax concomitant with gemcitabine and nab-paclitaxel is the first treatment to be FDA approved in nearly 30 ...
MassDevice

Novocure has reimbursement win for Optune Lua in Japan

Novocure (Nasdaq:NVCR) announced today that Japan’s Ministry of Health, Labour and Welfare approved reimbursement for its ...
Local 12 WKRC Cincinnati

Breakthrough device offers new hope for brain cancer survivors

CINCINNATI (WKRC) - A breakthrough device is providing new hope for brain cancer survivors, as demonstrated by the inspiring journey of Patty Young. Diagnosed with a brain tumor after suffering a ...
Business Wire

Novocure Announces National Reimbursement in Switzerland for Optune® in Combination With Temozolomide for the Treatment of Newly Diagnosed Glioblastoma

ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ:NVCR) announced today that the Swiss Federal Office of Public Health (BAG) has added Optune in combination with temozolomide to the List of ...
Seeking Alpha

U.S. FDA Approves Novocure’s Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer

Optune Pax concomitant with gemcitabine and nab-paclitaxel is the first treatment to be FDA approved in nearly 30 years for locally advanced pancreatic cancer Phase 3 PANOVA-3 trial showed a ...